|52 Week Rng||-|
|P/E Ratio (TTM)||-|
|P/E Ratio (Fwd)||-|
|Div & Yield||-|
Diagnostic & Research industry, long position. Rapidly growing industry. Very strong EBIT average growth rate: over the past 4 years of 36.48%. Steady revenue average growth over the past 4 years of 10.14%. Pays no dividends. Good beta of 1.62 in accordance to our target portafolio beta. High Price/Book Value of 3.87.
Buy order placed based on our strategy to invest in companies listed in Nasdaq and NYSE since the beginning of 2016. Each company is given an equal weight in our portfolio.